E2 treatment of PBMCs from lupus nephritis (LN) patients led to increased mRNA levels of TWEAK, which were abolished in the presence of ERα inhibitor methyl-piperidino-pyrazole (MPP) and ER antagonist Fulvestrant (ICI 182 780). The gene discussed is ESR1; the disease is lupus nephritis.